Trial Information

Summary: EKOS® Ultrasound Accelerated Thrombolysis with Lytic Bolus for Resolution of Arterial and Venous Occlusions [BRAVO study]

This study will evaluate a way of delivering blood clot dissolving drugs by providing a larger dose first (bolus) and then providing a lower dose of the drug. The EKOS system has been FDA cleared since 2004 and has demonstrated increased speed of breaking the clot. This post-marketing study is designed to provide additional information about use of a thrombolytic bolus.

To qualify, you must:

• Have an arterial or venous clot in your leg
• Have acute symptoms (for no more than 28 days)
• Be medically eligible for treatment with thrombolytic drugs

You will not qualify if you:

• Have an absolute contraindication for treatment with thrombolytic drugs
• Have been treated with mechanical thrombectomy (clot removal) prior to thrombolysis

Research being conducted by:
Jacob Cynamon, MD

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.